Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

• Results Overview

  Upadacitinib taken once daily as a pill significantly improved eczema symptoms compared to placebo, with 70% of patients on the 15mg dose and 80% on the 30mg dose showing major improvement in their eczema after 16 weeks.

• Study Summary

  Num Participants:

  847

  Study Type:

  Rct

  Control Group:

  Placebo Once Daily

  Efficacy End Points Treatment:

  {'EASI-75': 70, 'vIGA-AD response': 48}

  Efficacy End Points Control:

  {'EASI-75': 16, 'vIGA-AD response': 8}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Acne	Low	7
  Upper Respiratory Tract Infection	Low	9
  Nasopharyngitis	Low	8
  Headache	Low	5
  Elevation In Creatine Phosphokinase Levels	Medium	6

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected
  Acne	Low	2
  Upper Respiratory Tract Infection	Low	7
  Nasopharyngitis	Low	6
  Headache	Low	4
  Elevation In Creatine Phosphokinase Levels	Medium	3